Skip to main content
. 2022 Jan 21;17(1):118–122. doi: 10.18502/jovr.v17i1.10176

Table 1.

Patients' demographic data


Total patients 43
Age (yr), mean ± SD 65.39 ± 9.1
Sex Female 60% (n = 26)
Male 40% (n = 17)
Reason for aminobisphosphonates use Osteoporosis 56% (n = 24)
Metastasis 21% (n = 9)
Type of aminobisphosphonates Zoledronate 67% (n = 29)
Alendronate 14% (n = 6)
Pamidronate 12% (n = 5)
Risedronate 7% (n = 3)
SD, standard deviation